A Study to Evaluate The Effects of RO5545965 in Participants With Negative Symptoms of Schizophrenia Treated With Antipsychotics

Trial Profile

A Study to Evaluate The Effects of RO5545965 in Participants With Negative Symptoms of Schizophrenia Treated With Antipsychotics

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 23 Mar 2017

At a glance

  • Drugs RO 5545965 (Primary)
  • Indications Schizophrenia
  • Focus Pharmacokinetics; Therapeutic Use
  • Sponsors Roche
  • Most Recent Events

    • 23 Feb 2017 Planned End Date changed from 1 Dec 2016 to 1 Apr 2017.
    • 23 Feb 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Apr 2017.
    • 23 Feb 2017 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top